Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial

This Phase III study (n=402) found the addition of selinexor to bortezomib and dexamethasone was associated with improved progression-free survival (median 13.9 months vs 9.46 months with bortezomib plus dexamethasone; HR 0.70; 95% CI 0.53–0.93; p=0.0075).

Source:

The Lancet